Search Results

At Neurocrine, he initiated and led the effort to discover and develop orally active, nonpeptide GnRH Prior to Neurocrine, from 1995 to 1998, he co-founded ScienceMedia Inc. to develop eLearning solutions Between 1992 to 1995 he led contract research efforts at Biosym Technologies to develop and apply computational serves as board chair at Radionetics Oncology, a pharmaceutical company focused on the discovery and development

. 🚀 Develop New GPCR Skills Join Dr. Terry Kenakin’s unique course, Development of GPCR Ligands as Therapeutic Drugs , and gain essential insights into: 🔹 Drug Development Basics – PK-PD insights, absorption, and drug properties 🔹 Clearance 🎧 Join Remi Janicot as he shares his educational journey, passion for basketball and science, and career He discusses biased signaling in GPCR research, developing biosensors for G protein activity, networking

The company’s mission is to discover and develop highly effective cancer therapeutics by targeting heteromers Cardarelli is a drug development leader with extensive experience driving drug discovery teams in bringing biology, pharmacology, translational medicine, oncology, immuno-oncology, immunology, and clinical development While at BMS and Medarex, she led programs from target ID to clinical development that included, CXCL10 including anti-PD-1 patents, 22 EP patents, and greater than 100 global patents centered around therapeutic development

aGPCR signaling and function NovoiSMART - A new platform for GPCR antibody drug discovery Abstract Developing Novoprotein developed a NovoiSMART technology, utilizing mRNA-based immunization, which can overcome These examples underscore the potential of NovoiSMART technology in developing highly specific antibodies

As a developer, and more recently the lead developer of GPCRdb my day-to-day work centers around the maintenance and resource/tool development of GPCRdb and its sister databases.

As a developer, and more recently the lead developer of GPCRdb my day-to-day work centers around the maintenance and resource/tool development of GPCRdb and its sister databases.

John Traynor , Kathryn worked to develop and understand first-in-class allosteric modulators of opioid There she researched the beta-2 adrenergic receptor and developed assays to investigate real-time activity Kathryn’s passion is developing solutions to problems in whatever form is most efficient: novel instrumentation

led me to the Ottawa Hospital Research Institute (then the Moses and Rose Loeb Research Institute) to develop We are also currently developing the translational component of our research to capitalize on the druggability We hope our research will aid in the development of new therapeutic interventions for the alleviation

He is Chief Scientific Officer and co-founder of InterAx Biotech, where he specializes in the development Gebhard Schertler, he developed methods for kinetic mathematical analysis of GPCR signaling. Before focusing on the development of innovative mathematical modeling and simulation methods for drug Aurelien Rizk, a co-founder and CEO of Interax Biotech, shared about the company's development of a discovery of interdisciplinary teamwork in drug and technology development, noting the challenges of communication

Visit Website About Celtarys Research Celtarys Research develops and commercializes new chemical tools Her work focuses on organic synthesis, medicinal chemistry, and the development of GPCR-targeted tools Celtarys Research develops high-quality, fluorescently labeled ligands and innovative chemical biology Custom Development Customized fluorescent ligands developed in less than 3 months with optimal properties Custom Development Tailored fluorescent probes designed for unique research requirements.

belong to the super-family of G-protein coupled receptors (GPCR), the major molecular target for drug development allosteric modulators of D2R signaling and explores the potential usefulness of beta-arrestins for the development Beaulieu group is also actively implicated in translational research and industry collaboration to develop new drugs and drug development technology.

belong to the super-family of G-protein coupled receptors (GPCR), the major molecular target for drug development allosteric modulators of D2R signaling and explores the potential usefulness of beta-arrestins for the development Beaulieu group is also actively implicated in translational research and industry collaboration to develop new drugs and drug development technology.

Raimond Heukers , developed a nanobody platform within the research group and used this platform to develop He currently is focusing on the development of nanobody-based immuno tracers as part of the IMI/EFPIA

Monash Institute of Pharmaceutical Sciences (MIPS), a collaborative venture targeting new medicines development and CEO of Phrenix Therapeutics, a biotech spin-out from the Neuromedicines Discovery Centre that is developing particularly in the field of psychiatry, where he has led multiple projects into late stage preclinical development

Khorana’s lab made early key contributions and developed strategies to express, reconstitute and assay He also went on to discover a “counterion switch” in visual pigments and to develop strategies to assay Tom’s lab also developed an amber codon suppression method to genetically encode unnatural amino acids Early applications included “targeted photo-crosslinking,” and more recently, the parallel development

Sampedro-Castaneda, Marisol1, Claxton, Suzanne1, Skehel, Mark2, Ultanir, Sila K.1 1Kinases and Brain Development Mihaylov " I am a postdoctoral researcher in the kinases and brain development laboratory led by Dr Sila moved to King's College London, where my interest and passion for kinases in brain health and disease developed I have recently also developed a strong interest in adhesion GPCRs and in particular, Bai1. " Simeon

Department, Ken Vecchio helping set the foundation for the Nanoengineering Materials Research Center and developing Scientists and Engineers working at the nanoscale, specifically protein engineering and small molecule drug development

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based stream is now forming the basis of a new technology-based start-up company, HeptOME , to help screen and develop

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based stream is now forming the basis of a new technology-based start-up company, HeptOME , to help screen and develop

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based stream is now forming the basis of a new technology-based start-up company, HeptOME , to help screen and develop

This was followed by a postdoctoral role at the Polytechnic University of Turin (Italy), where he developed Now in a tenure-track position, his research spans the development of computational methods such as structure-based

has over 20+ years of experience working in a drug discovery environment mainly in a specialist assay development His current interests include the development of HTS fluorescence-based kinetic binding assays specifically

Pierre Eftekhari "Clinical physiologist and biologist , with more than 25 years of experience in drug development I have participated and initiated methodologies for development of pharmacologically active anti-GPCR

completed his postdoctoral training at MIT and Harvard Med School in the lab of Hidde Ploegh , where he developed Work in his independent laboratory is focused on developing new pharmacological tools via chemistry and

His team develops fluorescence-based and chemically engineered tools to study gpcr internalization and engagement in intact islets and neuronal circuits — insights that inform next-generation functional assay development His group develops imaging and chemical biology tools to reveal how GLP-1 and GIP receptors operate within

His research interest lies in understanding the molecular basis for human tumor development and how to Van Meir has developed novel therapeutic approaches for cancer using oncolytic adenoviruses and anti-angiogenic molecules and is currently developing novel small molecule inhibitors of the hypoxia-inducible factor His research aims to translate these novel agents to testing in clinical trials with the hope to develop the future, we plan to decipher the roles of N-glycosylation of ADGRG6 in organogenesis and tissue development

My project involved the development of FRET/BRET -based GPCR conformational biosensors, which can be I spent 2 1/2 years in his lab and developed novel conformational sensors for these intriguing receptors

Ben’s research focuses on Smoothened and other class F GPCRs which play essential roles in embryonic development within the primary cilium, a tiny antenna-shaped structure at the cell surface with critical links to development Ben studied developmental and cancer signaling as a postdoctoral fellow with Philip Beachy at Stanford

identification of small molecule regulators of these proteins, and progressing such ligands in drug development non-alcoholic steatohepatitis (NASH) and inflammatory diseases and Keltic Pharma Therapeutics (2020) which is developing

She developed expertise over the past two decades studying structure/function relationships of GPCRs the fundamental knowledge of GPCR biology and for the identification of drug targets and future drug development Manager, where they managed a technical support team providing scientific data analysis and database development contributed analytic support resulting in authorship of numerous scientific publications and new funding, and developed delivered technical presentations and software demonstrations to prospective customers worldwide, and developed